Stocks in play: HLS Therapeutics Inc.
Announces that results from a Quebec-based retrospective study examining the positive impact of pharmaceutical support programs on persistence with clozapine treatment have been published in the Journal of Clinical Pharmacology and Therapeutics. HLS Therapeutics Inc. shares T.HLS are trading unchanged at $3.70.
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.